Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further.
Despite the importance of traditional knowledge in many regions, an international treaty governing its control and exploitation does not exist yet—and talks have stalled. LSIPR reports.
As well as much other debate, the High Court’s decision in D’Arcy v Myriad Genetics has created uncertainty in terms of the patent eligibility of naturally occurring molecules other than DNA, says Tania Obranovich, special counsel at Watermark Intellectual Asset Management.
The High Court of Australia’s decision in Myriad has led some observers to hit the panic button and demand immediate legislative change, but only isolated naturally-occurring genes are affected and the ruling should be read in that light, says Grant Shoebridge of Shelston IP.
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports.
India’s progressive IP policies—and its status as ‘pharmacy of the developing world’ and lifeline for millions of people—are now under threat from many fronts. Yuanqiong Hu, IP advisor for Médecins Sans Frontières’s Access Campaign, explains more.
The judiciary system for the new Unified Patent Court has been the subject of much discussion. As part of a regular column, Paul England, senior associate at law firm Taylor Wessing and who chaired a recent discussion between a panel of experts, examines the issue.
Two writ petitions to the Delhi High Court have resulted in the formation of a committee tasked with devising approaches to promote expedited examination at the Indian Patent Office, as Pravin Anand of Anand and Anand reports.
Despite the SPC Regulation having been in existence for decades, applicants are still left to navigate uncertain waters on issues of fundamental importance when it comes to ‘combination’ therapies, as Michael Pears of Potter Clarkson reports.
As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports.